U.S. pharma big copyright scrapped two experimental weight loss tablets previous year—a after-each day pill, lotiglipron, because of elevated liver enzymes along with a two times-everyday pill, danuglipron, resulting from robust Uncomfortable side effects—but CEO Albert Bourla has cl